Cutaneous leishmaniasis in three Dutch military cohorts following jungle training in Belize

Travel Medicine and Infectious Disease

Volumn 9, Issue 3, 2011, Pages 153-160

  Van Thiel, P P A M ^a,b   Zeegelaar, J E ^a,c   Van Gool, T ^a   Faber, W R ^a   Kager, P A ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b Ministerie van Defensie   (Netherlands)

^c Flevoziekenhuis ^*  (Netherlands)

Author keywords

Belize; Cutaneous leishmaniasis; L. braziliensis; L. mexicana; Military

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; STIBOGLUCONATE SODIUM;

ARTICLE; BELIZE; CLINICAL ARTICLE; CRYOTHERAPY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GIEMSA STAIN; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LEISHMANIA BRAZILIENSIS; LEISHMANIA MEXICANA; NUCLEIC ACID SEQUENCE BASED AMPLIFICATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SKIN LEISHMANIASIS; SOLDIER;

ADOLESCENT; ADULT; ANTIMONY SODIUM GLUCONATE; BELIZE; HUMANS; LEISHMANIA BRAZILIENSIS; LEISHMANIA MEXICANA; LEISHMANIASIS, CUTANEOUS; MIDDLE AGED; MILITARY PERSONNEL; NETHERLANDS; RETROSPECTIVE STUDIES; SKIN; TREATMENT OUTCOME; TRYPANOCIDAL AGENTS;

EID: 79958809060     PISSN: 14778939     EISSN: 18730442     Source Type: Journal    
DOI: 10.1016/j.tmaid.2011.03.001     Document Type: Article

References (30)

1. Freedman DO, Weld LH, Kozarsky PE, Fisk T, Robins R, von Sonnenburg F, et al. for the Geosentinel Surveillance Network. Spectrum of disease and relation to place of exposure among ill returned travelers. N Engl J Med 2006;354:119-30. (Pubitemid 43076709)
2. Caumes E, Carrière J, Guermonprez G, Bricaire F, Danis M, Gentilini M. Dermatoses associated with travel to tropical countries: A prospective study of the diagnosis and management of 269 patients presenting to a tropical disease Unit. Clin Infect Dis 1995;20:542-8.
3. Jappe U. Unusual skin infections in military personnel. Clin Dermatol 2002;20:425-34.
4. Takafuji ET, Hendricks LD, Daubek JL, Mills McNeil K, Scagliola HM, Diggs CL. Cutaneous leishmaniasis associated with jungle training. Am J Trop Med Hyg 1980;29:512-20.
5. Sanchez JL, Diniega BM, Small JW, Miller RN, Andujar JM, Weiner PJ, et al. Epidemiologic investigation of an outbreak of cutaneous leishmaniasis in a defined geographic focus of transmission. Am J Trop Med Hyg 1992;47:47-54.
6. Hepburn NC, Tidman MJ, Hunter JA. Cutaneous leishmaniasis in British troops from Belize. Br J Dermatol 1993;128:63-8. (Pubitemid 23030150)
7. Green AD, Mason C, Spragg PM. Outbreak of cutaneous larva migrans among British military personnel in Belize. J Travel Med 2001;8:267-9. (Pubitemid 33000607)
8. Herwaldt BL. Leishmaniasis. Lancet 1999;354:1191-9.
9. Schwartz E, Hatz C, Blum J. New world cutaneous leishmaniasis in travelers. Lancet Infect Dis 2006;6:342-9. (Pubitemid 43737272)
10. Van Eys GJJM, Schoone GH, Kroon NCM, Ebeling SB. Sequence analysis of small subunit ribosomal RNA genes and its use for detection and identification of Leishmania parasites. Mol Biochem Parasitol 1992;51:133-42.
11. Van der Meide WF, Schoone GJ, Faber WR, Zeegelaar JE, de Vries HJ, Özbel Y, et al. Quantitative Nucleic Acid Sequence- Based Assay as a new molecular tool for detection and quantification of Leishmania parasites in skin biopsy samples. J Clin Microbiol 2005;43:5560-6. (Pubitemid 41612331)
12. th ed. London: WB Saunders Company Ltd; 1996. p. 1213-45.
13. Herwaldt BL, Berman JD. Recommendations for treating leishmaniasis with sodium stibogluconate (Pentostam) and review of pertinent clinical studies. Am J Trop Med Hyg 1992;46:296-306.
14. Lawn SD, Armstrong M, Chilton D, Whitty CJM. Electrocardiographic and biochemical adverse effects of sodium stibogluconate during treatment of cutaneous and mucosal leishmaniasis among returned travelers. Trans R Soc Trop Med Hyg 2006;100:264-9. (Pubitemid 43091825)
15. Palmer RA, Tran D, Hepburn NC, Ashton RE. The management of cutaneous leishmaniasis from Belize. Clin Exp Dermatol 2001;26:16-20. (Pubitemid 32204838)
16. Rojas R, Valderrama L, Valderrama M, Varona MX, Oeellette M, Saravia NG. Resistance to antimony and treatment failure in human Leishmania (Viannia) infection. J Infect Dis 2006;193: 1375-83. (Pubitemid 43673385)
17. Vergel C, Palacios R, Cadena H, Posso CJ, Valderrama L, Perez M, et al. Evidence for Leishmania (Viannia) parasites in the skin and blood of patients before and after treatment. J Infect Dis 2006;194:503-11. (Pubitemid 44162663)
18. Soto J, Medina F, Dember N, Berman J. Efficacy of permethrin-impregnated uniforms in the prevention of malaria and leishmaniasis in Colombian soldiers. Clin Infect Dis 1995;21: 599-602.
19. Llanos-Cuentas A, Tulliano G, Araujo-Castillo R, Miranda- Verastegui C, Santamaría-Castrellon G, Ramirez L, et al. Clinical and parasitic species risk factors for pentavalent antimonial treatment failure in cutaneous Leishmanasis in Peru. Clin Infect Dis 2008;46:223-31. (Pubitemid 351269161)
20. Navin TR, Arana BA, Arana FE, de Merida AM, Castillo AL, Pozuelos JL. Placebo-controlled clinical trial of meglumine antimonate (Glucantime) vs localized controlled heat in the treatment of cutaneous leishmaniasis in Guatemala. Am J Trop Med Hyg 1990;42:43-50. (Pubitemid 20060510)
21. Barrios LA, Costa JML, Netto EM, Vexenat COR, Cuba CC, Marsden PD. Intralesional glucantime in Leishmania braziliensis braziliensis infections. Trans R Soc Trop Med Hyg 1986; 80:173-4.
22. Bryceson A. Therapy in man. In: Peters W, Killick-Kendrick R, editors. The leishmaniases in biology and medicine. Clinical aspects and control, Vol. II. London: Academic Press; 1987. p. 847-907.
23. Davies CR, Llanos-Cuentas EA, Sharp SJ, Canales J, Leon E, Alvareze E, et al. Cutaneous leishmaniasis in the Peruvian Andes: factors associated with variability in clinical symptoms, response to treatment, and parasite isolation rate. Clin Infect Dis 1997;25:302-10. (Pubitemid 27364729)
24. Oliveira-Neto MP, Schubach A, Mattos M, Gonçalves de Costa SC, Pirmez C. Intralesional therapy of American cutaneous leishmaniasis with pentavalent antimony in Rio de Janeiro, Brazil e an area of Leishmania (V.) braziliensis transmission. Int J Dermatol 1997;36:463-8. (Pubitemid 27319639)
25. Schubach AO, Marzochi KBF, Moreira JS, Schubach TMP, Araujo ML, Vale ACF, et al. Retrospective study of 151 patients with cutaneous leishmaniasis treated with meglumine antimoniate. Rev Soc Bras Med Trop 2005;38:213-7.
26. Oliveira-Neto MP, Schubach A, Mattos M, Goncalves-Costa C, Pirmez C. A low-dose: antimony treatment in 159 patients with American cutaneous leishmaniasis: extensive follow-up studies (up to 10 years). Am J Trop Med Hyg 1997;57:651-5. (Pubitemid 28049378)
27. Gonzalez U, Pinart M, Rengifo-Pardo M, Macaya A, Alvar J, Tweed JA. Interventions for American cutaneous and mucocutaneous leishmaniasis. Cochrane Database Syst Rev; 2009. Issue 2. Art. No.: CD004834.DPI:10.1002/1451858. CD004834.pub2.
28. Lawn SD, Whetham J, Chiodini PL, Kanagalingam J, Watson J, Behrens RH, et al. New world mucosal and cutaneous leishmaniasis: an emerging health problem among British travellers. QJM 2004;97:781-8. (Pubitemid 39618569)
29. Gaafar A, Ismail A, El Kadaro AY, Hashim E, Khalil EAG, El Hassan AM. Necrotizing and suppurative lymphadenitis in Leishmania major infections. Trop Med Int Health 1996;1:243-9.
30. van Thiel PPAM, Leenstra T, de Vries HJ, van der Sluis A, van Gool T, Krull AC, et al. Cutaneous leishmaniasis (Leishmania major infection) in Dutch troops deployed in northern Afghanistan: epidemiology, clinical aspects, and treatment. Am J Trop Med Hyg 2010;83:1295-300.